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required percutaneous drainage none of them
were infected whereas 3 of the drain group
collections were infected.
The paper concludes that drainage after liver
resection is unnecessary. I have several problems
with this:
1. The power of this study to detect adverse
outcome in theno drain group is very limited
with approximately 50 patients in each group,
if a complication which occured with a rate of
5% in the drained group was three times more
frequent in the undrained group this would not
be detected.
2. The study does not show any advantage to not
draining. In fact, there was significantly higher
need for percutaneous post-op drainage.
3. Whilst two complications of drainage were
seen drain site abscess and drain site cancer
recurrence, ie. the former would seem a
relatively minor complication and even if the
drain site appeared to be the only site of
recurrence in the second patient, it would seem
likely that if enough viable tumour cells were
transplanted into the drain site that theywould
have developed at other sites in time.
David L. Morris
Professor of Surgery
Department of Surgery
The St George Hospital
Sydney NSW 2217 Australia
Is Chemoembolisation of Value
in Inoperable Primary Hepatocellular Carcinoma
ABSTRACT
Ryder, S. D., Rizzi, P. M., Metivier, E., Karani, J. and
Williams, R. (1996) Chemoembolisation with lipiodol and
doxorubicin: applicability in British patients with hepato-
cellular carcinoma, Gut, 38, 125-128.
Chemoembolisation has been extensively used as
primary treatment for unresectable hepatocellular
carcinoma (HCC). In this unit, 185 patients with a
new diagnosis of HCC not amenable to surgery were
seen between 1988 and 1991. Intended therapy for
these patients was chemoembolisation with doxo-
rubicin (60 mg/m2) and lipiodol, repeated at six week
intervals until it was technically no longer possible
o.r until complete tumour response had been
obtained. Chemoembolisation was possible in 67 of
the 185 (37%). Reasons for exclusion were portal vein
occlusion (n 36), decompensated cirrhosis (n 44),
distant metastases (n 5), diffuse tumour or unsui-
table anatomy (tumour or vasculature) (n=11),
patient refusal (n=11), and other (n=11). Patients
excluded from treatment survived for a median of 10
weeks (range 3 days-19 months). In patients treated,
18 had small HCC (4cm) and 49 had large or
multifocal HCC. Chemoembolisation was carried
out a median of two sessions for small and three
sessions for large tumours. Ten of 18 patients with
small HCC showed a 50% or greater reduction in
tumour size. Five of 49 patients with large or
multifocal tumours showed a response to treatment.
Median overall survival for treated patients was
36 weeks (range 3 days-4 years). One patient has
subsequently undergone liver transplantation with
no recurrence and minimal residual disease at
transplantation. Two other patients are alive three
years after chemoembolisation, one with no evidence
of recurrent disease. No patient was thought suitable
for surgery after their response to chemoembolisa-
tion. Chemotherapy related complications were seen
in 22%. Complications were significantly more
common in patients with larger tumours and poor
liver reserve. Five patients died as a result of chemo-
therapy related complications. In conclusion, only
one third of UK patients with unresectable HCC are
treatable by chemoembolisation. Results with smallHPB INTERNATIONAL 407
tumours are encouraging, with a high response rate
and the possibility of surgical intervention in
previously inoperable disease. Large tumours, how-
ever, show a poor response and significant incidence
of side effects, suggesting that this treatment offers
little benefit in advanced disease.
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PAPER DISCUSSION
Only a few years ago, surgery was the only
possibility for patients with hepatocellular carci-
noma. Today, with the large number of therapeu-
tic approaches being proposed, including some
with promising preliminary phase II results, it
could be said that the opposite is true, too many
possibilities for too few patients [1].
One of the main avenues of research has been
the locoregional approach using Lipiodol [2] as a
vector to deliver either a chemical agent or
irradiation directly into the tumour site, increas-
ing the antitumoural activity by embolism-in-
duced transitory ischaemia. The first trials using
chemoembolisation led to much enthusiasm,
which was abated when two phase III trials [3,
4] were unable to demonstrate any benefit in
survival over therapeutic abstention. Moreover,
in addition to negative results, a recently pub-
lished multicentric trial [4] also demonstrated the
limitations on the feasibility of chemoembolisa-
tion since among the 778 patients seen for
hepatocellular carcinoma in the 24 participating
centres over a 30 month period, only 96, i.e. 12%,
could be included in the study. The other patients
were excluded because of liver failure (30%),
vascular contraindications (22%), indications for
surgery (17% or alcoholisation (2%), extrahepatic
metastases (6%) and patient refusal (14%).
Ryder et al. report chemoembolisation data
obtained in a population of British patients. These
authors saw 195 patients in their unit over a 4-year
period. Surgery was proposed as first intention
therapy in 10 (5%). Despite very wide inclusion
criteria, only 67 (36%) of the non-operated
patients were treated with chemoembolism; liver
failure and portal thrombosis being the main
exclusion factors. The wide inclusion criteria
probably explain the high rate of treatment-
related side effects: 22% of the cases with 5 deaths
(8% of the treated patients). In our unit, we have
observed comparable results; morbidity and
mortality depend greatly on the severity of the
underlying liver disease. Ryder’s group clearly
demonstrate this fact since complications oc-
curred in 31% of their patients in class C in the
Child classification compared with 10% in classA
patients. These authors also note a clear relation-
ship between tumour size and frequency of
iatrogenic accidents described in 57% of the
patients with a tumour volume greater than 268
cm
3 (diameter 8 cm). Using response rate as a
measurement, efficacy was low, hardly 20%; it
was somewhat better in small tumours (56%) and
very low for multifocal or voluminous tumours
(10%). This relationship between tumour size and
response is well-known and logical. Vasculariza-
tion is generally better in small tumours than in
larger, often necrotic, tumours. The intensity of
Lipiodol retention, or more precisely of the thera-
peutic agent it vehicles, is directly correlated with
tumour size [5]. When a response is obtained, it
usually occurs rapidly after I or 2 sessions. These
authors did not obtain any response if none was
evidenced after the second injection. No bene-
ficial effect of treatment on survival could be
evidenced in this non-randomised trial. Never-
theless, the authors do report 4 patients who
survived more than 3 years including 1 who
later had liver transplantation after a complete
6-month response to the first embolisation.
Needless to say, this very interesting trial
confirms the dead-end situation we are in for
treatment of patients with hepatocellular carci-
noma. One could criticise the methodolody of
this trial since the chemolipiodolisation tech-
nique probably allowed exessively rapid dexo-
rubicin release so that the effect was similar to a
single embolisation [6], but without going into the408 HPB INTERNATIONAL
discussion on the efficacy of the chemoembolisa-
tion protocol, it can be noted that the technique
could only be used in about one-third of the
potential cases. In addition, the number of
patients who could be expected to benefit from
chemoembolisation without too great a risk-
patients with small tumours and low-grade
cirrhosis was small, less than 10 to 15% of the
potential cases.
Consequently, althoughwe have an apparently
impressive armamentarium of therapeutic op-
tions (resection, transplantation, alcoholisation,
chemoembolism), in clinical practice we can
propose them to only a very few patients. For
the large majority of our patients with hepatocel-
lular carcinoma, we have little to offer.
Further options will undoubtedly be deve-
loped in the future, and perhaps more impor-
tantly, better indications for optimal application
of those already in use will be defined. Theoreti-
cally, transplantation, resection, alcoholisation,
and perhaps chemoembolisation, might be bene-
ficial for patients with small tumours and low-
grade cirrhosis. To identify these patients, we
urgently need randomised trials comparing re-
section and transplantation, resection and alcoho-
lisation oreven resectionand chemoembolisation.
For patients who have a multifocal diffuse
tumour or a tumour developing in a severely
cirrhotic liver, i.e. approximately 50% of our
patients, it will be important to evaluate the eect
of less aggressive treatments such as antihormone
therapy or intra-arterial injections of radioactive
Lipiodol. This latter technique, resulting in one
randomised study in a better survival than best
supportive care achieved in patients with throm-
bosis of the portal vein [7], does not have the
disadvantages of chemoembolisation but has the
same efficacy. For the time being, it is unlikely that
any treatment should be proposed for patients
with advanced-stage cirrhosis, whatever the size
of the tumour, since the fatal course is determined
more by cirrhosis than by cancer.
With this paper, more than a decade of non-
randomised trials and unfortunately unfounded
enthusiasm draws to an end. The work reported
has clearly demonstrated the limitations of
chemoembolisation, emphasising the moderate
feasibility of the technique, its frequent and
severe side effects, and its rather disappointing
results. The reported data will help describe
several very different subpopulations who could
benefit from different treatments and point to the
urgent need for therapeutic trials to identify the
most appropriate technique in these subpopula-
tions.
Jean-Luc Raoul, MD, PhD
Centre E Marquis, BP 6279
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